Mechanisms of murine dendritic cell antitumor dysfunction in aging
/in International Publications, Malignant Melanoma, NSCLC /von 2008-12-13 / Cancer Immunol. Immunother. 2009 Dec;58(12):1935-9Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer – a phase II study
/in Hyperthermia, International Publications, Ovarian Cancer /von 2008-12-06 / Gynecol. Oncol. 2009 Feb;112(2):384-8Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer
/in International Publications, NSCLC /von 2008-12-04 / Lung Cancer 2009 Jul;65(1):1-8Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol
/in Hyperthermia, International Publications /von 2008-12-01 / Int J Hyperthermia 2008 Dec;24(8):649-62Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice
/in Hypernephroma, International Publications /von 2008-11-28 / Cancer Lett. 2008 Nov;271(2):333-41Dendritic cells in the skin–potential use for melanoma treatment
/in International Publications, Malignant Melanoma /von 2008-11-27 / Pigment Cell Melanoma Res 2009 Feb;22(1):30-41Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection
/in HIV/AIDS, International Publications /von 2008-11-26 / Clin. Vaccine Immunol. 2009 Feb;16(2):233-40Recent advances in cancer vaccines: an overview
/in Dendritic Cells, International Publications /von 2008-11-16 / Jpn. J. Clin. Oncol. 2009 Feb;39(2):73-80Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells
/in International Publications, Malignant Melanoma /von 2008-11-15 / Cancer Res. 2008 Nov;68(22):9441-50
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de